Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Oncotrophoblast glycoprotein 5T4 (TPBG) is a type I transmembrane glycoprotein involved in cell adhesion, migration, and Wnt signaling. It is highly expressed in various carcinomas but has limited expression in normal adult tissues, making it an attractive target for cancer therapy. It interacts with GIPC1 and plays a role in EMT and chemotaxis. Experimental therapies include monoclonal antibodies, antibody-drug conjugates, and cancer vaccines.
Monoclonal antibodies (e.g., mAb5T4) delivering response modifiers directly to tumors; Cancer vaccines (e.g., TroVax)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Oncotrophoblast Glycoprotein 5T4 (TPBG).